Subchondroplasty in the treatment of bone marrow lesions of the knee: Preliminary experience on first 15 patients by Pasqualotto, S. et al.
Subchondroplasty in the Treatment of Bone
Marrow Lesions of the Knee: Preliminary
Experience on First 15 Patients
Stefano Pasqualotto1 Andrea Vincenzo Sgroi1 Araldo Causero2 Paolo Di Benedetto2
Claudio Zorzi1
1Divisione di Ortopedia e Traumatologia, IRCCS Ospedale Classificato
Equiparato Sacro Cuore - Don Calabria, Negrar (Verona), Italy
2DAME Università degli studi di Udine, Clinica Ortopedica, Azienda
Sanitaria Universitaria Friuli Centrale, Udine, Italy
Joints 2019;7:174–181.
Address for correspondence Stefano Pasqualotto, MD, Divisione di
Ortopedia e Traumatologia, IRCCS Ospedale Classificato Equiparato
Sacro Cuore - Don Calabria, Via don A. Sempreboni, 5 - 37024 Negrar
(Verona), Italy (e-mail: stefano.pasqualotto20@gmail.com).
Keywords





Abstract Purpose The aim of this prospective study was to assess the effectiveness in terms of
pain relief and functional improvement of the Subchondroplasty procedure in the
treatment of osteoarthritis-related bone marrow lesions (BMLs) of the knee.
Methods The study included first 15 consecutive patients undergone to Subchon-
droplasty procedure for the treatment of chronic degenerative BMLs in which previous
conservative treatment have failed. Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) scores, Knee Injury and Osteoarthritis Outcome Scores
(KOOS), and visual analog scale (VAS) pain scores were obtained preoperatively and at
1, 6, and 12 months of follow-up.
Results WOMAC scores significantly improved from 39.720.2 before surgery to
26.816.1 at the 1-month follow-up (p¼0.045). A further significant improvement to
15.512.7 (p¼0.02) and to 8.63.1 (p< 0.01) was obtained both at 6-month and at
1-year follow-up. KOOS scores improved significantly from 47.5 16.6 before surgery
to 65.4 14.9 at 1 month (p¼0.013) and to 80.415.1 at 6-month follow-up
(p¼0.01). A further improvement to 85.6 15.1 was recorded 1 year postoperatively,
although nonsignificant. VAS score showed a significant improvement from
55.820.5 preoperatively to 36.2 16.9 at 1 month (p¼0.008) and to 18.217.3
at 6-month follow-up (p¼0.005). This further improved to 12.817.9 at 1-year follow-
up, although not significantly.
Conclusion Subchondroplasty procedure represents a safe and valid surgical option
in the treatment of osteoarthritis-related BMLs of the knee, providing an improvement
in terms of pain relief and functional recovery. Longer studies are required to evaluate
how long these improvements may last.
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Knee osteoarthritis (OA) is a degenerative process, which
affects not only the articular cartilage but the entire joint,
including synovium, ligaments, menisci, and periarticular
muscles and tendons.1,2 This process influences also the
subchondral bone (SCB) and alterations are seen both from
mechanical, morphological, and histochemical point of
view.3
SCB plays therefore a key role in the pathophysiology and
progression of OA. The presence of bone marrow lesions
(BMLs) in the setting of knee OA was correlated with pain,
clinical deterioration, decreased quality of life,4–7 and with
6.5- and 7-fold greater probabilities of OA progression.8
Moreover, the presence of BMLs was associated with an
accelerated progression to total knee arthroplasty (TKA).9–11
BMLs, defined as high-signal-intensity alterations
detected on magnetic resonance (MR) fluid-sensitive
sequences [T2/proton density with fat suppression and short
tau inversion recovery]with a decreased bonemarrow signal
intensity on T1-weighted image, are a common feature of
knee OA.12 Despite originally defined as bone marrow ede-
ma, several histological studies revealed that edema in the
region of BML is minimal.13,14 In the osteoarthritic process,
these areas are rather characterized by trabecular bone
microdamages and microcracks15–17 associated with altered
bone mineralization and increased bone remodeling.18
Moreover, vascular structure abnormalities,14,15 zone of
fatty marrow, necrosis, and bone marrow fibrosis were
detected.13,19,20
In recent years, therefore, interests were focused on
interventions directed toward the SCB to prevent or
reverse BMLs. Among these, Subchondroplasty (SCP)
(Zimmer Knee Creations, West Chester, Pennsylvania,
United States) is a procedure that utilizes an injectable,
synthetic, calcium phosphate (CaP) bone void filler to
treat chronic BMLs in which previous conservative treat-
ment failed.21 The goal of this procedure is to improve the
structural properties of the affected SCB and stimulate
SCB remodeling, with the aim of preventing bone collapse
and OA progression.21,22
Purpose of this preliminary study was to evaluate clinical
and functional outcomes of the treatment of OA-related knee
BML with SCP combined with arthroscopy.
Methods
This prospective 1-year follow-up case-series was con-
ducted on first 15 consecutive patients prospectively en-
rolled from February 2018 to October 2018 to undergo SCP
for the treatment of OA-related BML of the knee. The study
was approved by the institutional review board and writ-
ten informed consent was obtained from each patient
included.
Inclusion criteria were age between 40 and 75 years,
atraumatic and localized knee pain for at least 6 months
with failure of previous conservative treatments, and an MR
imaging (MRI) showing a BML located in the subchondral
region of the tibial plateau and/or femoral condyle, in
correspondence to the location of knee pain (►Fig. 1).
Exclusion criteria were: generalized knee pain, known
autoimmune disorders, active malignancies or infections,
OA> grade 3 according to Kellgren–Lawrence,23 patellofe-
moral OA> grade 3 according to Iwano classification24 asso-
ciated with symptoms related to patellofemoral joint, and
varus or valgus malalignment of the lower limb more than
10 degrees.
MRI images were analyzed with RadiAnt DICOM Viewer
(Medixant, Poznan, Poland) and BMLs were mapped in axial,
sagittal, and coronal view to measure the distance from the
joint line and the nearest cortex and to plan the direction of
the cannula.
Anteroposterior, lateral, and Merchant views were per-
formed to grade osteoarthritic changes whereas full-length
lower limb X-rays were performed to assess lower limb
alignment.
All the patients underwent the same clinical and ra-
diological evaluations and were assessed preoperatively
and at 1, 6, and 12 months with Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) and
Knee injury and Osteoarthritis Outcome Score (KOOS)
whereas pain was measured using the visual analog scale
(VAS).
All the patients underwent X-rays evaluations immedi-
ately after the procedure and at 1, 6, and 12 months postop-
eratively whereas MRI evaluations were performed at 6 and
12months. Intra- and postoperative complicationswere also
recorded.
Fig. 1 T2-weighted magnetic resonance imaging of patient’s left
knee before surgery showing bone marrow lesion of the medial
femoral condyle.
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Surgical Technique and Postoperative Management
After the preoperative planning, the SCP procedure was
performed with the patient in supine position under spinal
anesthesia.
According to preoperative planning, the entry point of the
cannula was marked on the skin with the aid of fluoroscopy
on both frontal and lateral view. A skin incision was then
performed and the cannula introduced until the bone.
A second check with the aid of the fluoroscopy was done
to identify the proper entry point. The cannula was then
introduced and drilling was continued until it reached the
lesion. A fluoroscopic check was done to control the exact
position of the cannula and to assess that all the three holes
of the side-delivery cannula were deep to the cortex and
oriented in the desired direction.
The AccuFill Bone Substitute Material (ETEX Corporation,
Cambridge,Massachusetts, United States) was then prepared
until the proper viscosity was reached and introduced into
the injured area, checking its distribution with the aid of
fluoroscopy (►Fig. 2).
After the SCP procedure, arthroscopy was performed to
check the intra-articular leakage of the bone substitute and to
evaluate and address intra-articular pathology such as chon-
dral flaps, loose bodies, and degenerative meniscal tears.
The postoperative management consisted of partial
weight-bearing with the aid of crutches for 1 week and
then full weight-bearing was allowed without any restric-
tions in terms of range of motion. Return to daily-life activi-
ties was encouraged as soon as tolerated.
Statistical Analysis
Statistical analyses were performed using RStudio v. 1.1.383
software (RStudio, Inc., Boston, Massachusetts, United
States) and a p-value of  0.05 was considered statistically
significant. The Kolmogorov–Smirnov and Shapiro–Wilk
tests were performed to assess the normality of the distri-
butions. Descriptive statistics were calculated: paired Stu-
dent’s t-test and the Wilcoxon matched-pairs signed rank
test were used to test for significant differences between
baseline and outcome score measurements.
Results
Ten of the 15 patientsweremalewhereas 5were femalewith
a mean age at the time of surgery of 53.69.4 years (range:
40–72). In seven cases, BML was located at the medial tibial
plateau, in three cases at the medial femoral condyle, and in
five cases both medial tibial plateau and medial femoral
condyle were involved. At the preoperative X-rays evalua-
tions, two patients had a grade 1 tibiofemoral OA, eight
patients had a grade 2, and five patients had a grade 3
according to Kellgren–Lawrence,23 whereas according to
Iwano classification24 five patients did not show any sign
of patellofemoral OA, seven patients had grade 1, and three
patients had grade 2. Six of the 15 patients have had previous
surgeryon the sameknee; among these, four have undergone
medial meniscectomy, one patient to an anterior cruciate
ligament (ACL) reconstruction associated with a medial
meniscectomy, and one patient has had a tibial tubercle
osteotomy (►Table 1).
Fig. 2 Intraoperative fluoroscopic anteroposterior (AP) image
showing the placement of the cannula and the diffusion of the calcium
phosphate (CaP) in the medial femoral condyle.
Table 1 Demographic data of patients treated with
subchondroplasty
No of patients 15
Mean age 53.6 years (range 40–72)
Sex 10 male
5 female
Side of knee (%) 9 right (60)
6 left (40)
Location of BML (%) 7 MTP (46.6)
3 MFC (20)
5 MTP and MFC (33.3)
Kellgren–Lawrence Grade I: 2 patients (13.33%)
Grade II: 8 patients (53.33%)
Grade III: 5 patients (33.33%)
Iwano Grade 0: 5 patients (33.33%)
Grade I: 7 patients (46.66%)











Abbreviations: ACL, anterior cruciate ligament; BML, bone marrow
lesion; MFC, medial femoral condyle; MTP, medial tibial plateau.
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Preoperative evaluations showed a mean WOMAC of
39.720.2, a mean KOOS total score of 47.516.6, and a
mean VAS score of 55.820.5mm.
At follow-up assessments, significant increases were
recorded in both WOMAC score, KOOS subscales, and VAS
scale as detailed below (►Table 2).
In comparison to preoperative values, WOMAC score
1 month postoperatively was 26.8 816.1, showing a
significant improvement (p¼0.045) which was main-
tained at 6-month follow-up when a mean value of
15.512.7 was obtained (p¼0.02) and also at 1-year
follow-up when a mean value of 8.63.1 was recorded
(p¼0.004).
KOOS score recorded 1 month postoperatively revealed a
significant improvement in comparison to preoperative val-
ues (p¼0.013) and this improvement was also recorded
6 months after the procedure when a mean value of
80.415.1 (p¼0.01) was obtained. KOOS at 1-year follow-
up revealed a little improvement with a mean score of
85.615.1 but no statistically significant differences were
found with the 6-month mean value. ►Fig. 3 shows the
distribution of KOOS subscales at the different evaluations.









WOMAC 39.720.2 26.8 16.1 15.512.7 8.6 3.1
VAS 55.820.5 36.2 16.9 18.217.3 12.8 17.9
KOOS–Pain 56.619.6 61.3 13.8 81.214.6 88.1 17.6
KOOS–Symptoms 56.518.9 68.7 14.6 81.214.1 90.9 11.3
KOOS–ADL 64.123.3 70.4 16.3 85.611.5 92.0 13.6
KOOS–Sports 23.723.2 44.8 24.8 66.523.9 66.9 20.9
KOOS–QoL 30.317.1 38.6 21.5 65.322.8 70.0 24.0
Abbreviations: ADL, activity of daily life; KOOS, Knee Injury and Osteoarthritis Outcome Scores; QoL, quality of life; SD, standard deviation; VAS,
visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Fig. 3 Line graphs of Knee Injury and Arthritis Outcome Score subscales preoperatively and at 1-, 6-, and 12-month follow-up.
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In comparison to preoperative value, mean VAS signifi-
cantly decreased to 36.216.9mm after 1month (p¼0.008)
and a further improvement was seen at 6-month follow-up
with a mean value of 18.217.3mm (p¼0.005). At 1-year
follow-up, VAS score showed a little progressionwith amean
value of 12.817.9 without reaching a statistically signifi-
cant difference from the value obtained at 6 months.
X-rays imaging in the postoperative period revealed in-
creased density in the site where the CaP were introduced
(►Fig. 4A–D) whereas MR images showed an area of low
signal intensity at the injection site (►Fig. 5B, C).
In terms of complications, only one patient underwent an
intraoperative complication with leakage of part of the CaP
outside the tibia, which was immediately removed by en-
larging the skin incisionwithout any adverse outcome for the
patient. None of the 15 patients showed a progression of the
disease with a collapse of the joint surfaces.
Discussion
The most important finding of this prospective study was
that SCP was able to provide a significant improvement in
terms of pain relief and knee functional capacity in patients
with chronic OA-related BMLs of the knee in which previous
conservative treatment have failed.
At 1-year follow-up, pain improvement was 43 points on
the VAS scale, in which the minimal clinically important
differences (MCIDs) is 20mm.25 Similarly, mean functional
improvement on the WOMAC was 31.1 points for which
MCID is 9.1,25 whereas KOOS showed a mean improvement
of 38.1 points with a MCID of 8 to 10 points.26
Traditionally, treatment of BMLs was based on nonsteroi-
dal anti-inflammatory drugs, analgesics, and restricted
weight-bearing especially in case of small lesions (<
3.5 cm2).27,28 More recently, pulsed electromagnetic
fields29,30 and extracorporeal shockwave therapy31–33
Fig. 4 (A–D) Anteroposterior and lateral postoperative X-rays
showing the increased density of the injection site (yellow circles)
1 month (A, B) and 6 months (C, D) after Subchondroplasty (SCP).
Fig. 5 (A–C) Fluid-sensitive magnetic resonance images showing the evolution from (A) preoperative bone marrow lesion (BML) at the medial
tibial plateau (white arrow) to (B) 6-month image which show an hypointense area corresponding to the injected calcium phosphate (CaP) with a
surrounding hyperintense rim (white circle). In 1-year image (C) CaP is assuming the intensity of the surrounding bone even though persist a mild
hypointense area (white circle).
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achieved good results in the treatment of BMLs of the knee,
though evidences are limited and long-term results have not
been investigated yet.
Likewise, intravenous bisphosphonates34–36 and prosta-
cyclin analogs37–39 showed promising results in the treat-
ment of OA-related BMLs and early stage osteonecrosis in
terms of both functional recovery and BML area reduction.
However, further studies are needed to clarify indications,
safety, and posology of these drugs.
In case of failure of conservative treatment, surgical
approach is recommended and SCP is a recently developed
procedure in which a bone substitute material composed of
CaP is employed to treat chronic nonhealing BMLs.40 The
results of the present study are largely consistent with some
of the other studies that evaluated the effect of SCP in the
treatment of BMLs of the knee.
Sharkey et al21were thefirst to describe the use of SCP in a
51-year-old womanwith a chronic OA-related BML associat-
ed with disabling knee pain resistant to previous conserva-
tive treatment. The follow-up at 31months showed excellent
clinical and functional outcomes and a complete resolution
of subchondral BML.
Farr and Cohen41 in a cohort of 59 patients with chronic
localized knee pain associated with subchondral BML
reported a significant pain reduction and functional im-
provement in 75% of patients at a mean follow-up of 14.8
months after SCP. However, the study showed a failure rate of
25% with 15 out of 59 patients who underwent a unicom-
partmental knee arthroplasty or a TKA at a mean follow-up
of 10.1 months.
Chatterjee et al42 in a retrospective study on 22 patients
with OA-related BMI reported a significant functional im-
provement (p<0.001) on the KOOS and Tegner–Lysholm
Knee Scoring Scale at a minimum follow-up of 6 months
after SCP associated with knee arthroscopy. Despite these
promising results, the authors advised against the use of SCP
since 10 out of 22 patients were considered clinical failure
according to clinical outcome categories of Tegner–Lysholm
Knee Scoring Scale, which was originally developed to eval-
uate ACL reconstruction and, therefore, not indicated in the
evaluation of the success rate of this treatment.43
Cohen and Sharkey,22 in a study on 66 patients, demon-
strated at 2-year follow-up a significant improvement of 4.5
point on the VAS scale and of 17.8 points on the International
Knee Documentation Committee Subjective Knee Evaluation
Form. Moreover, at 2- year follow-up, the authors registered
a failure rate of 30%, since 18 patients underwent TKA.
Cohen’s failure rate was higher in comparison with that of
the current study. However, it should be noted that patient
selection was different with Cohen’s cohort including
patients with moderate to severe OA, initially presented
for arthroplasty consultation who, to the contrary, were
excluded from the present study.
Bonadio et al,44 in a case-series of 5 patients with OA-
related BMLs treated with SCP, reported a significant pain
relief with a reduction of 7.2 points on the VAS scale and a
significant functional improvement of 32.8 points on the
KOOS. However, these results referred to a short-term fol-
low-up of 24 weeks.
More recently, Chua et al45 reported very good results in a
cohort of 12 patients with chronic localized knee pain
associated with a traumatic or degenerative subchondral
insufficiency fracture detected with MRI. The authors dem-
onstrated immediate postoperative pain relief that persisted
up to 1 year with a reduction of 5.4 points on the VAS scale.
Moreover, as in the present study, a significant functional
recovery with an early return to activity of daily living was
evidenced by an improvement of 34.7 points on the KOOS
and of 33.5 on the WOMAC scale at 1-year follow-up.
Despite the good results, the present study has some
limitations. First, the follow-up period is limited to 1 year
whereas a study with a longer follow-up would be able to
better evaluate the durability of the improvement. Second,
arthroscopic treatment of intra-articular pathology could
represent an important limitation since the relative contri-
bution of each procedure could not be evaluated. However, it
should be noted that several studies in patientswith knee OA
showed that arthroscopic debridement was not able to
provide a durable relief of OA symptoms.46–48 Third, we
acknowledge that our results refers to a small, nonrandom-
ized cohort without a control group.
In conclusion, based on the results of the present study
and literature considerations, it is possible to claim that SCP
in the treatment of OA-related BMLs provide a significant
improvement in terms of pain relief and functional recovery
although on short-term follow-up. This safe, mini-invasive,
and joint-sparing procedure could represent a valid second-
line therapeutic option in the treatment of chronic OA-
related BMLs in which previous conservative treatment has
failed. Anyway, randomized controlled studies with broader
cohort and longer follow-up are needed to confirm these
promising results and to detect real benefits that SCP could
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